- Price
- $300.79
- Day
- +3.00%
- Mkt Cap
- $6.03B
- 52W Range
- $132.21 – $326.63
- Volume
- 303.5K
- Beta
- 0.98
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Arrowstreet Capital Limited Partnership reduced its position in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 27.3% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,564 shares of the biotechnology company's stock after selling 5,472 shares during the period.
Read full article
Ashford Capital Management Inc. reduced its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 2.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 207,565 shares of the biotechnology company's stock after selling 6,213 shares during the quarter. Ligand Pharmaceuticals makes
Read full article
JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026.
Read full article
Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest names in tech, biotech, and retail in ways that could catch investors off guard. Find out which stocks got slashed and which ones earned surprise upgrades.
Read full article